Gleeson Paul, Bravi Gianpaolo, Modi Sandeep, Lowe Daniel
GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, UK.
Bioorg Med Chem. 2009 Aug 15;17(16):5906-19. doi: 10.1016/j.bmc.2009.07.002. Epub 2009 Jul 7.
A systematic analysis of data generated in key in vitro assays within GSK has been undertaken to identify what impact a range of common substituents have on a range of ADMET parameters. These include; P450 1A2, 2C9, 2C19, 2D6 and 3A4 inhibition, hERG inhibition, phosphate buffer solubility and artificial membrane permeability. We do this by identifying all matched molecular pairs, differing by the replacement of a hydrogen atom with a list of predefined substituents. For each substituent we calculate the mean difference in the ADMET parameter for all the matched molecular pairs identified, making a statistical assessment of the difference, as well as assessing the diversity for each example to ensure that the results can be generalized. We also relate the change in activity observed for each substituent to differences in their molecular properties in an effort to identify any structural alerts.
对葛兰素史克(GSK)关键体外试验中产生的数据进行了系统分析,以确定一系列常见取代基对一系列ADMET参数有何影响。这些参数包括:细胞色素P450 1A2、2C9、2C19、2D6和3A4抑制,人乙醚 - 去极化相关基因(hERG)抑制,磷酸盐缓冲液溶解度和人工膜通透性。我们通过识别所有匹配的分子对来实现这一点,这些分子对的差异在于用一系列预定义的取代基取代一个氢原子。对于每个取代基,我们计算所有识别出的匹配分子对的ADMET参数的平均差异,对差异进行统计评估,并评估每个实例的多样性,以确保结果具有普遍性。我们还将每个取代基观察到的活性变化与其分子性质的差异联系起来,以努力识别任何结构警示。